TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects von Haderski, Gary J, Kandar, Bojidar M, Brackett, Craig M, Toshkov, Ilia M, Johnson, Christopher P, Paszkiewicz, Geraldine M, Natarajan, Venkatesh, Gleiberman, Anatoli S, Gudkov, Andrei V, Burdelya, Lyudmila G

Volltext

Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9 von Brackett, Craig M., Greene, Kellee F., Aldrich, Alyssa R., Trageser, Nicholas H., Pal, Srabani, Molodtsov, Ivan, Kandar, Bojidar M., Burdelya, Lyudmila G., Abrams, Scott I., Gudkov, Andrei V.

Volltext

Abstract P4-04-02: A clinical-stage toll-like receptor 5 agonist, entolimod, boosts chemo-immunotherapy in pre-clinical TNBC by generating durable antitumor immunity von Brackett, Craig M, Aldrich, Alyssa R, Greene, Kellee F, Kandar, Bojidar, Veith, Jean, Burdelya, Lyudmila G, Abrams, Scott I., Gudkov, Andrei V

Volltext

A Toll-like Receptor 5 agonist entolimod mitigates radiation damage through a neutrophil-dependent mechanism von Brackett, Craig M, Greene, Kellee, Kandar, Bojidar, Trageser, Nicholas, Kandefer, Rachel, Pal, Srabani, Burdelya, Lyudmila, Gudkov, Andrei

Volltext